Publication | Open Access

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy

Hematological MalignancyLymphoid NeoplasiaMedicinePathologyHigh-dose TherapyRefractory B-cell LymphomaImmunotherapyOncologyRadiation OncologyEffective Salvage Regimen